@2024 Afarand., IRAN
ISSN: 1735-7675 Kowsar Medical Journal 2011;16(1):39-44
ISSN: 1735-7675 Kowsar Medical Journal 2011;16(1):39-44
Survival rate of patients suffering from gastric adenocarcinoma of Yazd city
ARTICLE INFO
Article Type
Original ResearchAuthors
Akhavan A. (* )Bashardoust N. (1 )
Moghimi M. (2 )
Seifadini A. (3 )
Salehi M. (3 )
(* ) Shahid Ramezanzadeh Ridiotherapy Center, Shahid Sadughi University of Medical Sciences, Yazd, Iran
(1 ) Department of Statistics, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
(2 ) Department of Pathology, Faculty of Medicine, Shahid Sadughi University of Medical Sciences, Yazd, Iran
(3 ) Aliebn-e-Abitaleb Faculty of Medicine, Yazd Branch, Islamic Azad University, Yazd, Iran
Correspondence
Address:Phone:
Fax:
ali52akhavan@yahoo.com
Article History
Received:Accepted:
ePublished:
ABSTRACT
Aims
Gastric cancer is one of the most common cancers in Iran and is one of the most frequent causes of death due to cancer. Despite progresses in treatment, it still causes much mortalities and its treatment is still a matter of debate in the world. This study was performed with the aim of investigating the factors affecting prognosis, the survival rate and effect of different treatments on survival in gastric adenocarcinoma patients.
Materials & Methods This analytical case series study was conducted on 47 gastric or cardia adenocarcinoma patient referring to Shahid-Ramezanzadeh Radiation Center from 2004 to 2009 and were selected by accessible sampling. Data was extracted from patients' records and follow up was conducted through telephone contacts. Kaplan-Meier curves and SPSS 13 software were used for data analysis.
Results Two-year and three-year survival of patients were 50% and 30%, respectively. Mean survival rate was 29.9 months and mean disease free survival rate was 12.95 months. Survival rate revealed a significant relation with disease stage (p=0.046), performed therapies (p=0.027) and surgical margin. Patients who had received a combination of surgery, chemotherapy and radiation therapy had the best survival. Survival had no relation with type of adenocarcinoma, tumor location or grade and chemotherapy regimen.
Conclusion Age, gender, surgery type, tumor location or grade and chemotherapy regimen do not affect survival, but the disease stage, performed therapies and surgical margin affect it. It seems that a combination of surgery, chemotherapy and radiation therapy would provide the best effect on patents' survival.
Materials & Methods This analytical case series study was conducted on 47 gastric or cardia adenocarcinoma patient referring to Shahid-Ramezanzadeh Radiation Center from 2004 to 2009 and were selected by accessible sampling. Data was extracted from patients' records and follow up was conducted through telephone contacts. Kaplan-Meier curves and SPSS 13 software were used for data analysis.
Results Two-year and three-year survival of patients were 50% and 30%, respectively. Mean survival rate was 29.9 months and mean disease free survival rate was 12.95 months. Survival rate revealed a significant relation with disease stage (p=0.046), performed therapies (p=0.027) and surgical margin. Patients who had received a combination of surgery, chemotherapy and radiation therapy had the best survival. Survival had no relation with type of adenocarcinoma, tumor location or grade and chemotherapy regimen.
Conclusion Age, gender, surgery type, tumor location or grade and chemotherapy regimen do not affect survival, but the disease stage, performed therapies and surgical margin affect it. It seems that a combination of surgery, chemotherapy and radiation therapy would provide the best effect on patents' survival.
CITATION LINKS